¹û¶³Ó°Ôº

XClose

¹û¶³Ó°Ôº Therapeutic Innovation Networks

Home
Menu

¹û¶³Ó°Ôº TINs Industry Club: Enabling life science and technology breakthroughs

27 June 2024

¹û¶³Ó°Ôº academics and representatives from six pharmaceutical companies joined the first roundtable for the newly launched ¹û¶³Ó°Ôº TINs Industry Club, aiming to identify common therapeutic R&D challenges.

A photo showing a group of people at a roundtable discussion.

Photo 1: Dr Jane Kinghorn, Director of the Translational Research Office, kick-started the roundtable by underscoring the newly-launched ¹û¶³Ó°Ôº TINs Industry Club’s position as a single collaborative platform for industry partners to access the research expertise at ¹û¶³Ó°Ôº.

On 27 June 2024, the ¹û¶³Ó°Ôº Translational Research Office (TRO) organised a roundtable for the newly launched ¹û¶³Ó°Ôº TINs Industry Club - a collaborative platform for companies to access research expertise within ¹û¶³Ó°Ôºâ€™s Therapeutic Innovation Networks (TINs).

The pilot event was attended by six major pharmaceutical companies, ¹û¶³Ó°Ôº scientists, our Expert in Residence, and the TRO team. Together, they identified common R&D challenges related to the therapeutic modality of small molecules and brainstormed how ¹û¶³Ó°Ôº academics can collaborate with industry to tackle unmet Ìýpatient needs. The event will pave the way for advancing innovative ideas into collaborative projects and for progressing similar discussions in other therapeutic and diagnostic areas.

¹û¶³Ó°Ôº TINs Industry Club is built on the Therapeutic Innovation Networks (TINs) initiated by the TRO, which have generated a ‘critical mass’ of research and healthcare innovation expertise from across academia and industry. ¹û¶³Ó°Ôºâ€™s six TINs are modality-focused agglomerations of researchers & other stakeholdersr, based around six of ¹û¶³Ó°Ôºâ€™s core biomedical research strengths :
i) Small Molecules,
ii) Biologics,

iii) Repurposing,
iv) Cell & Gene Therapy,
v) Devices & Diagnostics, and
i) Regenerative Medicine.

The launch of the ¹û¶³Ó°Ôº TINs Industry Club represents a step further in forming a single collaborative platform for industry partners to access the expertise of all six TINs, for the purpose of stimulating collaborations, co-developing challenge-led funding calls, and tackling unmet patient needs.

If you are a ¹û¶³Ó°Ôº researcher or an industry partner interested in getting involved, please contact:
Dr David Collier, Senior Business and Innovation Manager, david.collier@ucl.ac.uk

Ìý

A photo showing a group of people at a roundtable discussion.

Photo 2

Prof. Matthew Todd, Professor of Drug Discovery Pharma & Biochemistry and Chair of the Small Molecules TIN, chaired the wrap-up session of the pilot ¹û¶³Ó°Ôº TINs Industry Club Roundtable, inspiring further discussions on the common challenges .

Ìý

A photo showing a group of people at a roundtable discussion.
Ìý
A photo showing a group of people at a roundtable discussion.
Ìý
A photo showing a group of people at a roundtable discussion.

Photo 3a-c:
¹û¶³Ó°Ôº academics and representatives from six pharmaceutical companies joined the first roundtable for the newly launched ¹û¶³Ó°Ôº TINs Industry Club, aiming to identify commonÌýchallenges.

Ìý


Interested to stay informed of upcoming news, events and funding calls?

  • Subscribe to our newsletterÌýand you would automatically become a member of ¹û¶³Ó°Ôº TINs (Therapeutic Innovation Networks) and be the first to receive our event invitations

  • FollowÌýus on social media (,Ìý)Ìýand stay tuned to our news and updates.